Study of Metabolic Dysfunction-Associated Steatotic Liver Disease Among Sohag University Employees

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-09-01

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

* Metabolic dysfunction-associated steatotic liver disease (MASLD) is the latest term for steatotic liver disease associated with metabolic syndrome. MASLD is a common cause of chronic liver disease and is the leading cause of liver-related morbidity and mortality.
* The high prevalence of this disease has been fueled by the rapid rise in levels of sedentary behavior, low levels of physical activity, excess calorie intake relative to expenditure in nutritionally imbalanced and unhealthy diets. In parallel, the prevalence of poor metabolic health in adults from many countries is high, even in normal weight individuals.
* MASLD has been estimated to affect 30% of the adult population worldwide, with its prevalence increasing from 22% to 37% from 1991 to 2019 . The increasing prevalence of MASLD parallels the increasing prevalence of obesity and obesity-related diseases.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of NAFLD vs MAFLD Stigma on Quality of Life in Egyptian Patients

NCT06503068

NAFLD

RECRUITING

Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial

NCT06138821

Obesity Liver Diseases Liver Fibrosis +16 more

RECRUITING NA

Benefits of Trimetazidine in MASLD Patients

NCT06140953

Metabolic Associated Fatty Liver Disease

COMPLETED PHASE2

Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD

NCT07313007

MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease Metabolic Dysfunction-Associated Steatohepatitis (MASH)

NOT_YET_RECRUITING NA

Acceptability and Feasibility of a New Approach to Engage Patients With Steatotic Liver Disease in Physical Activity

NCT06446908

Liver Steatosis MASH MASLD

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Dysfunction-Associated Steatotic Liver Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Abdominal Ultrasound

Diagnostic non invasive Abdomibal Ultrasound will be done to quantify hepatic steatosis

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 100 Employees in Sohag University will be included in the study.

Exclusion Criteria

Employees with drug induced liver disease. Employees with chronic liver disease. Employees with decompensated liver cirrhosis. Employees with excessive alcohol consumption.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No